Search
Selected: All

N.sup.2 -Arylsulfonyl-L-argininamides and the pharmaceutically a

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically a

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 -Arylsulfonyl-L-argininamides and the pharmaceutically a

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceuti

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceuti

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 -naphthalenesulfonyl-L-argininamides and the pharmaceuti

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N.sup.2 Arylsulfonyl-L-argininamides and the pharmaceutically ac

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

N2-Arylsulfonyl-L-argininamides and the pharmaceutically accepta

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nerve growth factor

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

New peptides and a process for their preparation

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nitrosourea derivatives

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nona- and deca-peptide amide derivatives demonstrating high ovul

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nona- and decapeptides

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nona- and dodecapeptides for augmenting natural killer cell acti

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide and decapeptide agonists of luteinizing hormone rele

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide and decapeptide analogs of LHRH useful as LHRH antag

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH anta

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH anta

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide and decapeptide derivatives of luteinizing hormone r

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Nonapeptide for treating addictive drug withdrawal conditions

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent

  [ 0.00 ] – not rated yet Voters 0   Comments 0
  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.